memantine hydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Oct 1, 2007 → Jun 1, 2012
NCT ID
NCT00594737About memantine hydrochloride
memantine hydrochloride is a phase 3 stage product being developed by Lundbeck for Frontotemporal Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00594737. Target conditions include Frontotemporal Dementia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00594737 | Phase 3 | Completed |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 41 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 52 |
| Syntocinon | Brain Biotech | Phase 2 | 44 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 36 |
| PBFT02 | Passage Bio | Phase 1/2 | 33 |